Benzinga | Nov 9, 2021 04:25PM EST

Acorda Therapeutics Q3 EPS $(1.43) Beats $(1.56) Estimate, Sales $31.46M Beat $30.57M Estimate

Acorda Therapeutics (NASDAQ:ACOR) reported quarterly losses of $(1.43) per share which beat the analyst consensus estimate of $(1.56) by 8.33 percent. This is a 521.74 percent decrease over losses of $(0.23) per share from the same period last year. The company reported quarterly sales of $31.46 million which beat the analyst consensus estimate of $30.57 million by 2.90 percent. This is a 40.75 percent decrease over sales of $53.09 million the same period last year.